- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Patent holdings for IPC class A61K 39/395
Total number of patents in this class: 42707
10-year publication summary
2422
|
2867
|
3057
|
3461
|
3375
|
3487
|
3670
|
3468
|
2829
|
810
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Genentech, Inc. | 3742 |
855 |
Regeneron Pharmaceuticals, Inc. | 3650 |
676 |
Novartis AG | 11238 |
565 |
Amgen Inc. | 3779 |
511 |
F. Hoffmann-La Roche AG | 7958 |
465 |
Chugai Seiyaku Kabushiki Kaisha | 1259 |
440 |
The Regents of the University of California | 18943 |
425 |
Bristol-myers Squibb Company | 5080 |
371 |
Janssen Biotech, Inc. | 1347 |
367 |
Memorial Sloan-Kettering Cancer Center | 1789 |
267 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
265 |
Hoffmann-La Roche Inc. | 3060 |
259 |
Dana-Farber Cancer Institute, Inc. | 2455 |
249 |
Board of Regents, The University of Texas System | 5370 |
236 |
The Johns Hopkins University | 5377 |
222 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
206 |
Pfizer Inc. | 3322 |
205 |
Daiichi Sankyo Company, Limited | 1829 |
205 |
Eli Lilly and Company | 3645 |
202 |
Takeda Pharmaceutical Company Limited | 2961 |
188 |
Other owners | 35528 |